All In Biotech

Drug Trial Radar · NCT03667170

KN035 for dMMR/MSI-H Advanced Solid Tumors

Study of KN035 as Monotherapy in Patients With Advanced Mismatched Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

188

Actual

Start

Aug 22, 2018

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with KN035 monotherapy. For colorectal cancer participants, who are required to have been previously treated with standard therapies , other solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.

Conditions

  • Solid Tumor

Interventions

  • KN035Biological

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 2 years

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University Cancer Hospital, Peking University

    Beijing, Beijing Municipality, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Affiliated Tumor Hospital of Guangxi Medical University / Guangxi Cancer Hospital

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Eastern Theater Command General Hospital (Qinhuai Medical District)

    Nanjing, Jiangsu, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • The Affiliated Hospital of Qingdao University (Shibei Campus)

    Qingdao, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

  • The Second People's Hospital of Neijiang

    Neijiang, Sichuan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.